DM
BCRX icon

Deerfield Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Deerfield Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500,000
Closed -$2.78M – 92
2017
Q2 		$2.78M Buy
+500,000
New +$3.05M 0.15% 78

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Deerfield Management's BCRX Position: Q1 2026 in Review

Deerfield Management increased its BioCryst Pharmaceuticals (BCRX) stake by 4.9% in Q1 2026, buying an estimated $5.41M and bringing the position to 15,038,000 shares worth $143M. The position accounts for 1.69% of the portfolio, ranked #16.

Deerfield Management first reported a position in BCRX in Q3 2013 and has held it in 39 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Deerfield Management held 15,038,000 shares of BioCryst Pharmaceuticals worth $143M as of Q1 2026.
  • Deerfield Management bought 697,000 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $5.41M.
  • BioCryst Pharmaceuticals made up 1.69% of Deerfield Management's portfolio in Q1 2026, its #16 holding.
  • Deerfield Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 39 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.